“Our global quest is to improve the qualityof human life by enabling people to do more,
feel better and live longer”
GlaxoSmithKline Mission...
GSK Biologicals: 2005 Global Business
> £1,196 billion 200511% growth
> 50% US and Europe Infants
InfanrixEvery Second:45 doses of vaccines delivered
N°1 Provider
23% world Market Share
(2004)
GSK Biologicals: Contributing to World Health
We are a primary supplier to international organizations
We provide vaccines to developing world at preferential prices
We distributed approximately 90% of our vaccine doses to the developing world in 2006
– More than 1.5 billion doses of GSK vaccines were distributed worldwide
We work with policy-makers to establish vaccination policies and ensure vaccines are available to all
Worldwide Market Share of Vaccine Companies in 2005
Total Market: £ 5.2 billion
Source: GSK Bio estimates based on analyst reports and company press release
Other18%
Novartis5%
Merck11%
GSK23%
Wyeth13%
Sanofi Pasteur
21%
SP-MSD JV9%
Vaccine DevelopmentLong Lead Times and Big Investment - GSK Bio Core competencies
Identify Antigens
Produce Antigens
Test in Animals
Proof of Concept
Phase I III File
x
Registration
xup to £5.5m up to £30m £250m-500m
x x 3-5 yrs 2-3yrs 2-4 yrs 1 yr
x
Transfer Process to Manufacturing
Build Facility
II
Research (Inc. Immunology)
Preclinical Development (Inc. Formulation Science)
Clinical Development (Inc Post Marketing Surveillance
GSK Bio Milestones - 1956-2005
1956 Killed polio vaccine (Salk™ type: injectable)
1961 Live attenuated polio vaccine (Sabin™ type: oral)
1969 Rubella vaccine WORLD FIRST
1976 Thermostable measles vaccine WORLD FIRST
1984 Varicella vaccine WORLD FIRST
1986 Recombinant hepatitis B vaccine WORLD FIRST
1992 Hepatitis A vaccine WORLD FIRST
1992 Influenza vaccine (from SSW)
1994 Acellular pertussis vaccine (DTPa)
1996 Combined DTPw HBV ± Hib WORLD FIRST
1996 Combined hepatitis A&B WORLD FIRST
1997 Combined DTPa/Hib and DTPa IPV WORLD FIRST
1997 Priorix
1998 Combined DTPa IPV Hib vaccine
1999 DTPa booster vaccine
2000 DTPa HBV IPV (PeNta) (EU) WORLD FIRST
2000 DTPa HBV IPV/ Hib (Hexa)
2000 Combined Hepatitis A & Typhoid WORLD FIRST
2002 DTPa HBV IPV (Pediarix) (US)
2003 Combined meningitis ACW135 WORLD FIRST
2005 Rotavirus vaccine launch in Mexico
GSK Bio Milestones - 1956-2005 (cont’d)
Recent Launches In South Africa
Rotarix – vaccine to prevent Rota Virus GE
– Launched 2006 Vaccinated about 15 000 babies so far Prevented about 1000 hospitalizations
Infanrix Hexa
– Launched January 2007
– Six vaccines in one injection DTPa IPV Hib HB
HPV
The main cause of Cervical Cancer is HPV
Globally types 16, 18, 45 and 31 together account for more than 80% of Cervical Cancer cases
HPV
Up to 80% of women will be infected by an HPV infection at some point in their lives
Following HPV infection, your body does not always develop immunity and is therefore not protected against future infections.
Screening
Screening is the only way to prevent pre-cancerous lesions or the early signs of Cervical Cancer making it easier to treat successfully. However screening cannot prevent the cause of Cervical Cancer